Alternative to tissue-based
biopsies, for when tissue
can be difficult to extract

LiquidGx™ is a non-invasive cancer test
for selecting relevant solid tumor therapies

Sample Report
Sample Report
Information Sheet
Information Sheet
LiquidGx_tm LiquidGx
A non-invasive cancer test that can easily become part of your workflow
LiquidGX_iocn1 LiquidGx
Established guidelines recommend liquid biopsy when tissue biopsy is not feasible
LiquidGX_iocn2 LiquidGx
Utilizes proprietary technology to analyze ctDNA/RNA to accurately detect cancer-driving mutations
LiquidGX_iocn3 LiquidGx
Measures actionable mutations from blood for the selection of solid tumor targeted treatment
LiquidGX_iocn4 LiquidGx
Testing at multiple time points allows quantitative monitoring for drug resistance markers
LiquidGx_tm-e1528984431305 LiquidGx
A non-invasive cancer test that can easily become part of your workflow
LiquidGX_iocn1-e1528984817362 LiquidGx

Established guidelines
recommend liquid biopsy
when tissue biopsy is not
feasible

LiquidGX_iocn2-e1528984831396 LiquidGx

Utilizes proprietary
technology to analyze
ctDNA/RNA to accurately
detect cancer-driving
mutations

LiquidGX_iocn3-e1528984868182 LiquidGx

Measures actionable
mutations from blood for
the selection of solid tumor
targeted treatment

LiquidGX_iocn4-e1528984886741 LiquidGx

Testing at multiple time
points allows
quantitative monitoring
for drug resistance
markers

MSI Status for PD-1 Immune
Checkpoint Inhibitors

In addition to actionable mutations for targeted therapy, LiquidGx™ provides microsatellite instability (MSI) status. MSI status can predict a predisposition to mutations as a result from impaired DNA mismatch repair (MMR) and help predict if a tumor will respond to anti-PD-1 therapy.

MSI status is determined by detecting the length of mononucleotide repeats at five genomic sites (BAT-25, BAT-26, NR-21, NR-24, and NR-27)

Tumor-Specific_DNA_Slippage_events-300x181 LiquidGx

A shift in repeat length(formation of a second peak) observed in the cell-free DNA (cfDNA) compared to genomic DNA (gDNA) at 3 or more sites indicates MSI-High

Inactive_Cytotoxic_T-CellTumor_Cell-300x181 LiquidGx

T-cell cannot recognize tumor cell as foreign

Inactive_Cytotoxic_T-CellTumor_Cell_Antibody-300x181 LiquidGx

With anti-PD1 therapy, T-Cell can now recognize tumor cell as foreign

Clear, Color-Coded Results

Same_Tumor_Type_icon_green LiquidGx

Therapies Linked to Variants of Known Clinical Significance

Lack_of_clinical_benefit_icon LiquidGx

Resistance or Interaction Variants of Known Clinical Significance

Different_Tumor_Type_icon_blue LiquidGx

Therapies Linked to Variants of Potential Clinical Significance

clinical_trials_icon_purple LiquidGx

Clinical Trials to Consider

For each variant found, will provide up to 5
relevant clinical trials with geographic
considerations

Download Sample Report

Two Platforms Available:

qPCR

ALK BRAF EGFR KRAS
  • Single gene analytes via qPCR that can be run individually or multiplexed

  • Offers accurate results within 3 business days so results can be in-hand before a patient’s first oncology consultation

  • Limit-of-detection 0.01%, the equivalent of finding one DNA fragment in 10,000

  • Optimal fusion detection via ctRNA

NGS

AKT1 ALK BRAF EGFR ERBB2 HRAS
KIT KRAS MAP2K1 MET NRAS PDGFRA
PIK3CA PTEN RET ROS1 TP53
  • Next Generation Sequencing test, coverage of >170 variants in 17 genes frequently
    mutated in cancer

  • Turnaround time of 3-5 business days, which is faster than standard protocols including reflexive FISH and immunohistochemistry testing

  • Includes MSI for selection of anti-PD1 therapy

  • Limit-of-detection 0.1% (SNV, fusion), 2% (MSI), 2.5 total gene copies (CNV)

  • Input includes both ctDNA and ctRNA allowing for optimal fusion detection including, novel fusions

Both platforms include:

EGFR T790M and EGFR C797S variant detection for drug resistance monitoring

LiquidGx™ NGS quantifiable detects variants – producing actionable results

   Also detectable by qPCR   

Genes Variants Potential Treatment Implications
AKT1 E17K May benefit from treatment with temsirolimus and everolimus
ALK  Fusions: EML4, KIF5B, TFG, STRN May benefit from treatment with crizotinib, ceritinib, or alectinib
L1196M, G1202R, I1171T/N/S, F1174L/S, E1210K, 1151Tins, C1156Y,L1198F,V1190L, D1203N, S1206Y/C, G1269A Predictive of crizotinib resistance. May demonstrate benefit with ceritinib, alectinib, and brigatinib
BRAF  V600E, V600K, V600D, V600G, V600M, V600R May benefit from treatment with
vemurafenib, dabrafenib,
vemurafenib + cibimetinib, or
dabrafenib + trametinib
L597R, L597Q,L597S, L597V, D594G, D594V May result in clinical trial recommendations
EGFR  L858R, E746_A750del, E746_A750delELREA, G719A, G719C, G719S, E746_S752delinsA, A763_Y7g4insFQEA, K745_A750del, L747_S752del, additional Exon19_del May benefit from treatment with gefitinib, erlotinib, or afatinib
Exon20_ins May demonstrate lack of clinical benefit to gefitinib and erlotinib
 T790M May benefit from treatment with osimertinib if previously treated with 1st or 2nd generation EGFR-TKIs
 C797S May demonstrate acquired resistance to osimertinib
CNV May benefit from treatment with gefitinib, erlotinib, or afatinib
ERBB2 Exon20_ins, G776L, G776_777insVC May benefit from treatment with trastuzumab and afatinib
CNV May benefit from treatment with trastuzumab and lapatinib
HRAS G12R, G12V, G13R, G13R, Q61R May benefit from treatment with MEK inhibitors
KRAS  G12C, G12V, G12D, G12A, G12R, G12S,
G13D, G13D,
G13A, G13R, G13S, G13V,
K117N, A146P, A146T, A146V,
Q61H, Q61K, Q61L, Q61P, Q61R
Often associated with poor prognosis including resistance to gefitinib, erlotinib, cetuximab, panitumumab
KIT K642E, Exon_11 SNVs May benefit from treatment with imatinib, nilotinib, sunitinib, and sorafenib
MAP2K1 C121S, P124S, P124L May result in clinical trial recommendations
MET CNV May benefit from treatment with crizotinib, erlotininb, and gifitinib
Exon14_skipping May benefit from treatment with crizotinib
NRAS G12C, G12R, G12W, G12A, G12D, G12V Often associated with poor prognosis including resistance to gefitinib, erlotinib, cetuximab, panitumumab
G13C, G13R, G13A, G13D, G13V May benefit from treatment with sorafenib
Q61K, Q61R, Q61L, Q61H, Q61E, Q61P Often associated with resistance to gefitinib, erlotinib, cetuximab, and panitumumab but may benefit from sorafenib
PIK3CA E542K, E545K, H1047R May benefit from treatment with temsirolimus and everolimus
PDGFRA D842V Often associated with resistance to imatinib and sunitinib
PTEN R130*, R130G, R130Q, R130P, R130L, R233*, K267*, T319* May result in clinical trial recommendations
RET M918T, C634R, C634Y, C634W May benefit from treatment with vandetanib
Fusions: CCDC6, NCOA4, KIF5B May benefit from treatment with vandetanib and cabozantinib
ROS1 Fusions: LRIG3, TPM3, EZR, SDC4, GOPC, SLC34A2, CD74 May benefit from treatment with crizotinib
TP53 R175H, G245S, R248Q, R248W, R249S, R273H, R2473C, R2482W May result in clinical trial recommendations
MSI Status Mononucleotides: BAT-25, BAT-26, NR-21, NR-24, and NR-27 May benefit from treatment with Pembrolizumab and Nivolumab

LiquidGx™ complements Admera Health’s suite of molecular diagnostics:

oncogxselect-1200x191 LiquidGx

Solid tumor profiling for targeted therapy selection following established guidelines

Learn more
oncogxone-1200x191 LiquidGx

Comprehensive solid tumor profiling for targeted therapy selection

Learn more